A Century of Progress in Diabetes Care with Insulin: A History of Innovations and Foundation for the Future

Lee, Seung‐Hwan; Yoon, Kun‐Ho

doi:10.4093/dmj.2021.0163

Cited by 27 publications

(19 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further optimizations of insulin in the following decades were conducted to improve its performance [ 129 ]. Recombinant proteins were cloned and used for expression in the 1980s [ 128 , 130 ]. Similar to insulin, TCS is also a natural product.…”

Section: Discussionmentioning

confidence: 99%

A Sixty-Year Research and Development of Trichosanthin, a Ribosome-Inactivating Protein

Lü

Wong

Shaw

2022

Toxins

View full text Add to dashboard Cite

Tian Hua Fen, a herbal powder extract that contains trichosanthin (TCS), was used as an abortifacient in traditional Chinese medicine. In 1972, TCS was purified to alleviate the side effects. Because of its clinical applications, TCS became one of the most active research areas in the 1960s to the 1980s in China. These include obtaining the sequence information in the 1980s and the crystal structure in 1995. The replication block of TCS on human immunodeficiency virus in lymphocytes and macrophages was found in 1989 and started a new chapter of its development. Clinical studies were subsequently conducted. TCS was also found to have the potential for gastric and colorectal cancer treatment. Studies on its mechanism showed TCS acts as an rRNA N-glycosylase (EC 3.2.2.22) by hydrolyzing and depurinating A-4324 in α-sarcin/ricin loop on 28S rRNA of rat ribosome. Its interaction with acidic ribosomal stalk proteins was revealed in 2007, and its trafficking in mammalian cells was elucidated in the 2000s. The adverse drug reactions, such as inducing immune responses, short plasma half-life, and non-specificity, somehow became the obstacles to its usage. Immunotoxins, sequence modification, or coupling with polyethylene glycerol and dextran were developed to improve the pharmacological properties. TCS has nicely shown the scientific basis of traditional Chinese medicine and how its research and development have expanded the knowledge and applications of ribosome-inactivating proteins.

show abstract

Section: Discussionmentioning

confidence: 99%

A Sixty-Year Research and Development of Trichosanthin, a Ribosome-Inactivating Protein

Lü

Wong

Shaw

2022

Toxins

View full text Add to dashboard Cite

show abstract

“…In general, the countries encourage scientific, technological, and innovation development, as a strategic element for the economical advance and improvement of health systems (Kruk et al, 2018). Following this incentive, in the year of the 100 th anniversary of the discovery of insulin, numerous innovations occurred in glucose monitoring in patients with DM, becoming the "cornerstone of medical science" (Lee & Yoon, 2021), changing the way of treating these patients, with the advent of research and technological and innovative products, offering new solutions and benefits in the quality of life of people with diabetes.…”

Section: Technological Development and Innovation In Healthcarementioning

confidence: 99%

Mapping of Patents Related to The Development of Products for Diabetic Neuropathy: a technological prospection from 2010 to 2022

Barros

Pereira²,

Souza³

et al. 2022

RSD

View full text Add to dashboard Cite

Diabetic neuropathy is a complication of diabetes that occurs in 40-60 million diabetics worldwide and is associated with other chronic diseases. Besides that, there are no prospective studies that present the state of the technique about technologies developed to circumvent this important public health problem. Given the above, this study aims to carry out a technological prospection about the products developed for diabetic neuropathy in the period 2010-02/02/2022. To this end, a technological prospection was carried out at the INPI and ESPACENET patent office’s always making a parallel between Brazilian reality in comparison with international companies. Therefore, in this period, it was found that the countries that produced the most patents on the subject were China, the United States, and Japan, and the company that published the most patents in this period was Beijing Luyuan Qiuzheng Technology Dev. Co Ltd. Thus, the data from this study showed that Brazil did not produce patents on the subject in this period and that China, the United States, and Japan were the countries that showed the greatest interest in technological development aimed at this disease, which affects millions of people all over the world.

show abstract

“…Frequent injections can also increase pain and wounds caused by needles also increase the risk of infection [ 5 , 6 ]. Realizing the use of insulin through non-injection routes has become a new direction of human research [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Glucose-Responsive Silk Fibroin Microneedles for Transdermal Delivery of Insulin

et al. 2023

View full text Add to dashboard Cite

Microneedles (MNs) have attracted great interest as a drug delivery alternative to subcutaneous injections for treating diabetes mellitus. We report MNs prepared from polylysine-modified cationized silk fibroin (SF) for responsive transdermal insulin delivery. Scanning electron microscopy analysis of MNs’ appearance and morphology revealed that the MNs were well arranged and formed an array with 0.5 mm pitch, and the length of single MNs is approximately 430 μm. The average breaking force of an MN is above 1.25 N, which guarantees that it can pierce the skin quickly and reach the dermis. Cationized SF MNs are pH-responsive. MNs dissolution rate increases as pH decreases and the rate of insulin release are accelerated. The swelling rate reached 223% at pH = 4, while only 172% at pH = 9. After adding glucose oxidase, cationized SF MNs are glucose-responsive. As the glucose concentration increases, the pH inside the MNs decreases, the MNs’ pore size increases, and the insulin release rate accelerates. In vivo experiments demonstrated that in normal Sprague Dawley (SD) rats, the amount of insulin released within the SF MNs was significantly smaller than that in diabetic rats. Before feeding, the blood glucose (BG) of diabetic rats in the injection group decreased rapidly to 6.9 mmol/L, and the diabetic rats in the patch group gradually reduced to 11.7 mmol/L. After feeding, the BG of diabetic rats in the injection group increased rapidly to 33.1 mmol/L and decreased slowly, while the diabetic rats in the patch group increased first to 21.7 mmol/L and then decreased to 15.3 mmol/L at 6 h. This demonstrated that the insulin inside the microneedle was released as the blood glucose concentration increased. Cationized SF MNs are expected to replace subcutaneous injections of insulin as a new modality for diabetes treatment.

show abstract

A Century of Progress in Diabetes Care with Insulin: A History of Innovations and Foundation for the Future

Cited by 27 publications

References 84 publications

A Sixty-Year Research and Development of Trichosanthin, a Ribosome-Inactivating Protein

A Sixty-Year Research and Development of Trichosanthin, a Ribosome-Inactivating Protein

Mapping of Patents Related to The Development of Products for Diabetic Neuropathy: a technological prospection from 2010 to 2022

Glucose-Responsive Silk Fibroin Microneedles for Transdermal Delivery of Insulin

Contact Info

Product

Resources

About